Theresa A. Boyle

3.7k total citations · 1 hit paper
59 papers, 2.1k citations indexed

About

Theresa A. Boyle is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Theresa A. Boyle has authored 59 papers receiving a total of 2.1k indexed citations (citations by other indexed papers that have themselves been cited), including 31 papers in Oncology, 28 papers in Pulmonary and Respiratory Medicine and 25 papers in Molecular Biology. Recurrent topics in Theresa A. Boyle's work include Lung Cancer Treatments and Mutations (23 papers), Cancer Immunotherapy and Biomarkers (13 papers) and Cancer Genomics and Diagnostics (11 papers). Theresa A. Boyle is often cited by papers focused on Lung Cancer Treatments and Mutations (23 papers), Cancer Immunotherapy and Biomarkers (13 papers) and Cancer Genomics and Diagnostics (11 papers). Theresa A. Boyle collaborates with scholars based in United States, China and Türkiye. Theresa A. Boyle's co-authors include Fred R. Hirsch, Caicun Zhou, Hui Yu, David L. Rimm, Edward W. Bernton, Yossi Mizrachi, Marti Jett, Harris A. Gelbard, David J. Volsky and Robert W. Keane and has published in prestigious journals such as Journal of Clinical Investigation, The Journal of Experimental Medicine and Journal of Clinical Oncology.

In The Last Decade

Theresa A. Boyle

55 papers receiving 2.0k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

PD-L1 Expression in Lung Cancer

2016 336 citations Theresa A. Boyle, Fred R. Hirsch et al. Journal of Thoracic Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Theresa A. Boyle United States	21	853	732	700	354	344	59	2.1k
Daekwan Seo South Korea	30	645 0.8×	177 0.2×	1.4k 2.0×	343 1.0×	532 1.5×	46	2.6k
Anli Zhang China	22	473 0.6×	184 0.3×	811 1.2×	736 2.1×	276 0.8×	47	2.1k
Ombretta Salvucci United States	27	842 1.0×	121 0.2×	919 1.3×	793 2.2×	250 0.7×	37	2.2k
Salvatore J. Coniglio United States	21	657 0.8×	115 0.2×	1.0k 1.5×	625 1.8×	326 0.9×	29	2.3k
Christiane R. Maroun Canada	19	393 0.5×	118 0.2×	1.1k 1.6×	635 1.8×	117 0.3×	40	2.0k
Barbara Molon Italy	22	1.1k 1.2×	116 0.2×	664 0.9×	1.6k 4.5×	246 0.7×	33	2.5k
Alessandra Battaglia Italy	25	733 0.9×	228 0.3×	711 1.0×	828 2.3×	195 0.6×	83	2.6k
Travis W. Bainbridge United States	15	702 0.8×	107 0.1×	773 1.1×	320 0.9×	194 0.6×	23	1.6k
Leomar Y. Ballester United States	29	273 0.3×	413 0.6×	752 1.1×	133 0.4×	449 1.3×	108	1.9k
Akrit Sodhi United States	33	1.4k 1.6×	183 0.3×	1.7k 2.4×	532 1.5×	740 2.2×	64	4.3k

Countries citing papers authored by Theresa A. Boyle

Since Specialization

Citations

This map shows the geographic impact of Theresa A. Boyle's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Theresa A. Boyle with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Theresa A. Boyle more than expected).

Fields of papers citing papers by Theresa A. Boyle

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Theresa A. Boyle. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Theresa A. Boyle. The network helps show where Theresa A. Boyle may publish in the future.

Co-authorship network of co-authors of Theresa A. Boyle

This figure shows the co-authorship network connecting the top 25 collaborators of Theresa A. Boyle. A scholar is included among the top collaborators of Theresa A. Boyle based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Theresa A. Boyle. Theresa A. Boyle is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Sen, Triparna, Virginia Corbett, Sonam Puri, et al.. (2025). Pulmonary neuroendocrine neoplasms: the molecular landscape, therapeutic challenges, and diagnosis and management strategies. The Lancet Oncology. 26(1). e13–e33. 8 indexed citations

Lin, Chi‐Ying, Theresa A. Boyle, Jeremy D. Schmahmann, et al.. (2024). Early-Life Social Determinants of SCA6 Age at Onset, Severity, and Progression. The Cerebellum. 23(4). 1449–1456.

Alontaga, Aileen Y., Pedro Cano, John Puskas, et al.. (2024). Implementation of a High-Accuracy Targeted Gene Expression Panel for Clinical Care. Journal of Molecular Diagnostics. 26(8). 685–699. 2 indexed citations

Saltos, Andreas, Tawee Tanvetyanon, Ben Creelan, et al.. (2023). Phase II randomized trial of first-line pembrolizumab and vorinostat in patients with metastatic NSCLC (mNSCLC): Final results.. Journal of Clinical Oncology. 41(16_suppl). 9125–9125. 2 indexed citations

Yu, Xiaoqing, Mengyu Xie, Joseph Johnson, et al.. (2023). Combination IFNβ and Membrane-Stable CD40L Maximize Tumor Dendritic Cell Activation and Lymph Node Trafficking to Elicit Systemic T-cell Immunity. Cancer Immunology Research. 11(4). 466–485. 9 indexed citations

Saltos, Andreas, Ben Creelan, Tawee Tanvetyanon, et al.. (2023). A phase I/IB trial of binimetinib in combination with erlotinib in NSCLC harboring activating KRAS or EGFR mutations. Lung Cancer. 183. 107313–107313. 3 indexed citations

Owen, Dwight H., Regan M. Memmott, Gregory A. Otterson, et al.. (2023). Novel STK11 differentiation phenotype classifier STK11-DPC: Immunosuppressive tumor microenvironment (TME) and response to immune checkpoint blockade (ICB) in STK11-deficient NSCLC.. Journal of Clinical Oncology. 41(16_suppl). 2626–2626. 1 indexed citations

Chiappori, Alberto, Ben Creelan, Tawee Tanvetyanon, et al.. (2022). Phase I Study of Taminadenant (PBF509/NIR178), an Adenosine 2A Receptor Antagonist, with or without Spartalizumab (PDR001), in Patients with Advanced Non–Small Cell Lung Cancer. Clinical Cancer Research. 28(11). 2313–2320. 50 indexed citations

Majumder, Anurima, et al.. (2022). Abstract 1101: CTNNB1 mutation can mediate resistance to EGFR, ALK and KRAS targeted therapies. Cancer Research. 82(12_Supplement). 1101–1101. 2 indexed citations

10.

Tunali, Ilke, Yan Tan, Jhanelle E. Gray, et al.. (2021). Hypoxia-Related Radiomics and Immunotherapy Response: A Multicohort Study of Non-Small Cell Lung Cancer. JNCI Cancer Spectrum. 5(4). 31 indexed citations

11.

Gray, Jhanelle E., et al.. (2021). Biomarkers of therapeutic response with immune checkpoint inhibitors. Annals of Translational Medicine. 9(12). 1040–1040. 3 indexed citations

12.

Ward, Nathan P., Yun Pyo Kang, Aimee Falzone, Theresa A. Boyle, & Gina M. DeNicola. (2020). Nicotinamide nucleotide transhydrogenase regulates mitochondrial metabolism in NSCLC through maintenance of Fe-S protein function. The Journal of Experimental Medicine. 217(6). 37 indexed citations

13.

Gray, Jhanelle E., Andreas Saltos, Tawee Tanvetyanon, et al.. (2019). Phase I/Ib Study of Pembrolizumab Plus Vorinostat in Advanced/Metastatic Non–Small Cell Lung Cancer. Clinical Cancer Research. 25(22). 6623–6632. 104 indexed citations

14.

Kellish, Patrick, Masmudur M. Rahman, Akbar Nawab, et al.. (2019). Oncolytic virotherapy for small-cell lung cancer induces immune infiltration and prolongs survival. Journal of Clinical Investigation. 129(6). 2279–2292. 40 indexed citations

15.

Ng, Terry L., Hui Yu, Derek Smith, et al.. (2018). Preselection of lung cancer cases using FGFR1 mRNA and gene copy number for treatment with ponatinib.. Journal of Clinical Oncology. 36(15_suppl). 12095–12095. 3 indexed citations

16.

Smith, Matthew A., Hans‐Ulrich Schildhaus, Vincent Vuaroqueaux, et al.. (2017). MET–GRB2 Signaling-Associated Complexes Correlate with Oncogenic MET Signaling and Sensitivity to MET Kinase Inhibitors. Clinical Cancer Research. 23(22). 7084–7096. 11 indexed citations

17.

Quinn, Gwendolyn P., Rebecca D. Pentz, Teresita Muñoz-Antonia, et al.. (2017). Patient, caregiver and physician perspectives on participating in a thoracic rapid tissue donation program. Patient Education and Counseling. 101(4). 703–710. 2 indexed citations

18.

Ren, Shengxiang, Fred R. Hirsch, Marileila Varella‐Garcia, et al.. (2014). Atypical Negative ALK Break-Apart FISH Harboring a Crizotinib-Responsive ALK Rearrangement in Non–Small-Cell Lung Cancer. Journal of Thoracic Oncology. 9(3). e21–e23. 50 indexed citations

19.

Baschal, Erin E., Jean Jasinski, Theresa A. Boyle, et al.. (2012). Congruence as a measurement of extended haplotype structure across the genome. Journal of Translational Medicine. 10(1). 32–32. 5 indexed citations

20.

Ohm, Angela M., et al.. (2011). Protein Kinase C δ Is a Downstream Effector of Oncogenic K-ras in Lung Tumors. Cancer Research. 71(6). 2087–2097. 45 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact